Summit Therapeutics, Inc. (SMMT)
15.62
-0.40
(-2.50%)
USD |
NASDAQ |
May 19, 09:57
Summit Therapeutics Research and Development Expense (Quarterly) : 132.62M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Revolution Medicines, Inc. | 341.62M |
| BioMarin Pharmaceutical, Inc. | 178.80M |
| Relay Therapeutics, Inc. | 70.56M |
| Alnylam Pharmaceuticals, Inc. | 364.87M |
| Amgen, Inc. | 1.719B |